Miro Venturi – CEO, Sintetica
Dr Miro Venturi of Swiss injectable anaesthetics and analgesics specialist Sintetica outlines his career journey, why personalised medicine is about taking a holistic view across the entire patient journey, and…
Since its founding in 1943, the Swiss Tropical Institute (STI), now Swiss Tropical and Public Health Institute (Swiss TPH) has become a world-renowned Institution for teaching, research and services in the field of International Health Development.
The multi- and cross-disciplinary activities and experience of scientific laboratory studies, conceptual clinical work and practical transfer of technical expertise to health system planning and programmes in local, national and partner countries are the building blocks of the Swiss TPH´s success.
Today over 700 colleagues from 40 nations work worldwide for the Swiss TPH in research, teaching and service provision with the single goal to facilitate and contribute to health development worldwide with a strong focus on low and middle income countries.
As an associate institute of the University of Basel, the Swiss TPH takes part in teaching within the medical, philosophy, natural sciences, and historical philosophy faculties, as well as is engaged in post-graduate education and advanced training on national and international levels.
Contact
Swiss Tropical and Public Health Institute
P.O. Box
4002 Basel
Main Secretariat & Travel Clinic:
Socinstrasse 57
4051 Basel
Phone +41 61 284 81 11
Dr Miro Venturi of Swiss injectable anaesthetics and analgesics specialist Sintetica outlines his career journey, why personalised medicine is about taking a holistic view across the entire patient journey, and…
Nerum Pharmaceuticals, a Switzerland-based start-up, is supplying high-grade cannabis products to nine countries around the world. CEO and Co-Founder Alex Pombo highlights how the company leverages their unique Swiss-Colombia connection,…
Eric ten Kate, VP for Global Life Science at logistics and distribution firm Agility, highlights how the company responded to the unprecedented challenges thrown up by the COVID-19 pandemic and…
Redalpine Venture Partners’ Dr Michael Sidler highlights some of the key trends in the European biotech VC space, the funding and operational strategies that successful start-ups in Europe are utilising,…
Dr Remo Gujer gives an overview of the BMS footprint in Switzerland and Austria, the ongoing integration of legacy Celgene operations, market access challenges, clinical trials, and the importance of…
Laurent Massuyeau introduces Swiss biosimilar commercialisation specialist iQone healthcare, why it made sense to base the company in Switzerland, its partnership deal with Korean biosimilar giant Celltrion, and where iQone’s…
After an illustrious career in oncology R&D, contributing greatly to the development of cutting-edge cancer therapies at Novartis and Gilead, Alessandro Riva, MD joined biotech Ichnos Sciences as its founding…
Thomas F. Schmidt, country manager of Roche Pharma in its home market of Switzerland discusses adjusting to his first role in general management, the particularities of the Swiss market, and…
Andrea Emilio Rizzoli of the Dalle Molle Institute for Artificial Intelligence, among the top 10 in the world in its field of research, outlines the focus of the Institute today,…
This article forms part of Healthcare & Life Sciences Review: Switzerland February 2021, a comprehensive up-to-date country report on the Swiss pharma market, featuring data snapshots, feature articles, exclusive interviews…
hystrix medical is an online contracting marketplace for medical devices and replenishing/repeat purchase products in hospitals. CEO Philippe Hügli explains the company’s origins and model today, his ambitions beyond the…
Biotech veteran Brian O’Callaghan introduces ObsEva – a Swiss-based firm focused on women’s health –, his motivations to join the company – which is on the verge of transforming into…
See our Cookie Privacy Policy Here
